biotech Archives - Vista Partners LLC | HomeVista Partners LLC

Ivonescimab vs Keytruda: The High‑Stakes HARMONi‑3 Interim That Could Flip the Script for Summit Therapeutics -( $MRK $SMMT $IBB $XBI )

by John F. Heerdink, Jr. 3 days ago 173Views 0Likes

Summit Therapeutics’ (SMMT) latest tweak to its clinical playbook has turned what was already one of biotech’s higher‑stakes stories into something closer to appointment viewing for Wall Street. A Phase 3 Trial Adds a Plot Twist Summit now plans an interim progression‑free…

Eupraxia’s Latest Raise: A Diffusphere-Fueled War Chest Aims at GI Disease -( $EPRX $IBB $XBI $SNY)

by John F. Heerdink, Jr. February 21, 2026 151Views 0Likes

In a market that has grown wary of “story stocks,” Eupraxia Pharmaceuticals (NASDAQ: EPRX) just delivered something refreshingly old-fashioned: a fully closed, upsized equity offering that actually funds a clinical plan rather than a marketing slogan. The clinical‑stage biotech, which trades on…

GeoVax Tries on Its 2026 “Breakout Year” Jacket — And It Might Just Fit -( $GOVX $IBB $XBI )

by John F. Heerdink, Jr. February 17, 2026 329Views 0Likes

GeoVax Labs (NASDAQ: GOVX) is stepping into 2026 talking like an inflection‑year story—and, unusually for biotech, it has the clinical, regulatory and manufacturing pieces to at least justify the wardrobe change. While capital remains tight, the company is pairing late‑stage Mpox vaccine…

Eupraxia Pharmaceuticals: Injecting New Life Into EoE — One Microsphere at a Time -( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. February 9, 2026 285Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) may still wear the “clinical-stage” name tag, but its stock has been behaving like it already found a seat at the grown‑ups’ table on Wall Street. Over the past year, shares have climbed roughly 160%, far outpacing the…

Eli Lilly’s Weight-Loss Empire Just Got Heavier with $2.4B Acquisition – And So Did Its Market Cap -( $LLY $NVO $SPY )

by John F. Heerdink, Jr. February 9, 2026 229Views 0Likes

Eli Lilly (LLY) has once again muscled its way to the top of the healthcare league tables, with its stock climbing as investors double down on the idea that obesity drugs are less a fad and more a new asset class. The…

Inside Biopharma’s 2025 Deal Wave: Record Licensing, Big Pharma M&A and a Frozen IPO Market -( $JPM $IBB $XBI $LLY $MRK $NVS $PFE )

by John F. Heerdink, Jr. January 21, 2026 177Views 0Likes

Biopharma spent 2025 behaving like a sector that has finally read the fine print on the cost of capital—and decided to let someone else pick up the bar tab. Licensing and M&A stepped into the role IPOs used to play, and did…

Eupraxia Pharmaceuticals: The Small‑Cap Biotech Quietly Seeking To Build a Billion‑Dollar Plus EoE Franchise -( $EPRX $IBB $XBI )

by Vista Partners LLC December 12, 2025 448Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX, $6.40, +1.59% today and +85.51% over the last year) is emerging as a standout small‑cap biotech, transforming a once‑niche GI indication and routine endoscopy visits into a compelling, scalable growth platform, underpinned by a mid‑teens price target from…

Inside GeoVax’s Big-League Scientific Upgrade: Global Experts Join the Fight Against Cancer and Deadly Viruses -( $GOVX $AZN $IBB $XBI )

by Vista Partners LLC December 10, 2025 396Views 0Likes

GeoVax’s (NASDAQ: GOVX) latest boardroom move reads like a biotech who’s-who casting call, with the Atlanta-based vaccine developer quietly assembling a scientific brain trust that looks less like a small-cap advisory board and more like a Davos side panel on immunology. A…

Can PD1xVGEF Bifunctional Antibodies displace Keytruda and Opdivo in Immuno-Oncology? – $MRK $BMY $SMMT $BNTX $GLYC $NAYA

by Vista Partners LLC January 9, 2025 369Views 0Likes

Tag: biotech

Ivonescimab vs Keytruda: The High‑Stakes HARMONi‑3 Interim That Could Flip the Script for Summit Therapeutics -( $MRK $SMMT $IBB $XBI )

Eupraxia’s Latest Raise: A Diffusphere-Fueled War Chest Aims at GI Disease -( $EPRX $IBB $XBI $SNY)

GeoVax Tries on Its 2026 “Breakout Year” Jacket — And It Might Just Fit -( $GOVX $IBB $XBI )

Eupraxia Pharmaceuticals: Injecting New Life Into EoE — One Microsphere at a Time -( $EPRX $SNY $XBI )

Eli Lilly’s Weight-Loss Empire Just Got Heavier with $2.4B Acquisition – And So Did Its Market Cap -( $LLY $NVO $SPY )

Inside Biopharma’s 2025 Deal Wave: Record Licensing, Big Pharma M&A and a Frozen IPO Market -( $JPM $IBB $XBI $LLY $MRK $NVS $PFE )

Eupraxia Pharmaceuticals: The Small‑Cap Biotech Quietly Seeking To Build a Billion‑Dollar Plus EoE Franchise -( $EPRX $IBB $XBI )

Inside GeoVax’s Big-League Scientific Upgrade: Global Experts Join the Fight Against Cancer and Deadly Viruses -( $GOVX $AZN $IBB $XBI )

Can PD1xVGEF Bifunctional Antibodies displace Keytruda and Opdivo in Immuno-Oncology? – $MRK $BMY $SMMT $BNTX $GLYC $NAYA

Your Guide To Staying Informed In The Markets